Intravenous immunoglobulin as adjunctive therapy for juvenile spasms

Ulrike Bingel, Joseph Pinter, Márcio Sotero de Menezes, Jong M. Rho

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Intravenous immunoglobulin has been reported to be an effective treatment for infantile spasms. Juvenile spasms are electrically and clinically similar to infantile spasms but occur in a later age group. We retrospectively reviewed the charts of five children (aged 4.5-11.5 years) at our institution. Their primary seizure type was juvenile spasms and they were treated with a single inpatient course of intravenous immunoglobulin (400 mg/kg/day intravenously for 5 consecutive days) on an adjunctive basis. Seizure frequency was determined from parental reports. By 3 months after treatment, improvement (a 50-92% reduction in seizure frequency) was noted in four patients; sustained benefit was seen in three patients for up to 12 months. One patient showed no response at 3 and 6 months and had an increase in seizure frequency at 1 year. We conclude that single-course intravenous immunoglobulin can be effective as adjunctive therapy for juvenile spasms and that benefit can persist for many months. However, larger controlled, prospective clinical trials are needed to validate this unconventional treatment modality for specific seizure types such as juvenile spasms.

Original languageEnglish (US)
Pages (from-to)379-382
Number of pages4
JournalJournal of Child Neurology
Volume18
Issue number6
StatePublished - Jun 1 2003
Externally publishedYes

Fingerprint

Intravenous Immunoglobulins
Spasm
Seizures
Infantile Spasms
Therapeutics
Controlled Clinical Trials
Inpatients
Age Groups

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health

Cite this

Bingel, U., Pinter, J., Sotero de Menezes, M., & Rho, J. M. (2003). Intravenous immunoglobulin as adjunctive therapy for juvenile spasms. Journal of Child Neurology, 18(6), 379-382.

Intravenous immunoglobulin as adjunctive therapy for juvenile spasms. / Bingel, Ulrike; Pinter, Joseph; Sotero de Menezes, Márcio; Rho, Jong M.

In: Journal of Child Neurology, Vol. 18, No. 6, 01.06.2003, p. 379-382.

Research output: Contribution to journalArticle

Bingel, U, Pinter, J, Sotero de Menezes, M & Rho, JM 2003, 'Intravenous immunoglobulin as adjunctive therapy for juvenile spasms', Journal of Child Neurology, vol. 18, no. 6, pp. 379-382.
Bingel, Ulrike ; Pinter, Joseph ; Sotero de Menezes, Márcio ; Rho, Jong M. / Intravenous immunoglobulin as adjunctive therapy for juvenile spasms. In: Journal of Child Neurology. 2003 ; Vol. 18, No. 6. pp. 379-382.
@article{cee61ab9a41e4e4fbd8a8e30626ce079,
title = "Intravenous immunoglobulin as adjunctive therapy for juvenile spasms",
abstract = "Intravenous immunoglobulin has been reported to be an effective treatment for infantile spasms. Juvenile spasms are electrically and clinically similar to infantile spasms but occur in a later age group. We retrospectively reviewed the charts of five children (aged 4.5-11.5 years) at our institution. Their primary seizure type was juvenile spasms and they were treated with a single inpatient course of intravenous immunoglobulin (400 mg/kg/day intravenously for 5 consecutive days) on an adjunctive basis. Seizure frequency was determined from parental reports. By 3 months after treatment, improvement (a 50-92{\%} reduction in seizure frequency) was noted in four patients; sustained benefit was seen in three patients for up to 12 months. One patient showed no response at 3 and 6 months and had an increase in seizure frequency at 1 year. We conclude that single-course intravenous immunoglobulin can be effective as adjunctive therapy for juvenile spasms and that benefit can persist for many months. However, larger controlled, prospective clinical trials are needed to validate this unconventional treatment modality for specific seizure types such as juvenile spasms.",
author = "Ulrike Bingel and Joseph Pinter and {Sotero de Menezes}, M{\'a}rcio and Rho, {Jong M.}",
year = "2003",
month = "6",
day = "1",
language = "English (US)",
volume = "18",
pages = "379--382",
journal = "Journal of Child Neurology",
issn = "0883-0738",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Intravenous immunoglobulin as adjunctive therapy for juvenile spasms

AU - Bingel, Ulrike

AU - Pinter, Joseph

AU - Sotero de Menezes, Márcio

AU - Rho, Jong M.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Intravenous immunoglobulin has been reported to be an effective treatment for infantile spasms. Juvenile spasms are electrically and clinically similar to infantile spasms but occur in a later age group. We retrospectively reviewed the charts of five children (aged 4.5-11.5 years) at our institution. Their primary seizure type was juvenile spasms and they were treated with a single inpatient course of intravenous immunoglobulin (400 mg/kg/day intravenously for 5 consecutive days) on an adjunctive basis. Seizure frequency was determined from parental reports. By 3 months after treatment, improvement (a 50-92% reduction in seizure frequency) was noted in four patients; sustained benefit was seen in three patients for up to 12 months. One patient showed no response at 3 and 6 months and had an increase in seizure frequency at 1 year. We conclude that single-course intravenous immunoglobulin can be effective as adjunctive therapy for juvenile spasms and that benefit can persist for many months. However, larger controlled, prospective clinical trials are needed to validate this unconventional treatment modality for specific seizure types such as juvenile spasms.

AB - Intravenous immunoglobulin has been reported to be an effective treatment for infantile spasms. Juvenile spasms are electrically and clinically similar to infantile spasms but occur in a later age group. We retrospectively reviewed the charts of five children (aged 4.5-11.5 years) at our institution. Their primary seizure type was juvenile spasms and they were treated with a single inpatient course of intravenous immunoglobulin (400 mg/kg/day intravenously for 5 consecutive days) on an adjunctive basis. Seizure frequency was determined from parental reports. By 3 months after treatment, improvement (a 50-92% reduction in seizure frequency) was noted in four patients; sustained benefit was seen in three patients for up to 12 months. One patient showed no response at 3 and 6 months and had an increase in seizure frequency at 1 year. We conclude that single-course intravenous immunoglobulin can be effective as adjunctive therapy for juvenile spasms and that benefit can persist for many months. However, larger controlled, prospective clinical trials are needed to validate this unconventional treatment modality for specific seizure types such as juvenile spasms.

UR - http://www.scopus.com/inward/record.url?scp=0037767567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037767567&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 379

EP - 382

JO - Journal of Child Neurology

JF - Journal of Child Neurology

SN - 0883-0738

IS - 6

ER -